Indian officials revealed that branded treatments for diabetes and heart disease are far more expensive than their generic alternatives, as reported Business Standard Friday.
"Yes, it is a fact that some branded medicines are many times costlier than generic medicines," chemicals and fertilisers minister Mansukh Mandaviya stated.
The government said that the prices of branded heart drugs, such as amlodipine/atenolol, ramipril and losartan/hydroclorothiaze, are eight-fold to 10-fold higher than generics in Jan Aushadhi Kendras.
The country also explained that branded glimepiride is 10-fold more expensive that generic versions, while, branded metformin is only three-fold more expensive than generics.
Regarding antibiotics, leading brands of ofloxacin are nearly four times more costly than generic versions.
Mandaviya noted "the group of secretaries [has] made several recommendations for promotion of generic medicines."
To read more NewsPoints articles, click here.